Comparison of the Effects of Empagliflozin,Liraglutide,and Metformin in the Treatment of Patients with New-onset Type 2 Diabetes and Non-alcoholic Fatty Liver Disease
Objective To analyze the efficacy of emgagliflozin,liraglutide and metformin on new type 2 diabetes melli-tus with nonalcoholic fatty liver disease.Methods 150 patients with type 2 diabetes combined with non-alcoholic fatty liver admitted to Linyi Lanling Economic Development Zone Hospital from October 2022 to October 2023 were selected as the study objects.According to the lottery method,they were divided into group A,group B and group C,with 50 cases each.Group A received empagliflozin,Group B received liraglutide,and Group C received metformin.Blood glucose,lipids and liver function indexes were compared in 3 groups.Results Before treatment,there was no statistically significant difference of blood glucose,lipid and liver function indexes were compared in the 3 groups(all P>0.05).After treatment,the blood glucose parameters in groups A and B were lower than those in group C,and the differences were statistically significant(both P<0.05).Total cholesterol and low densith lipoprotein in group B were lower than those in groups A and C,and the differences were statistically significant(all P<0.05).Liver function index in groups A and B were lower than that in group C,and the differences were statistically significant(both P<0.05).Conclusion For new patients with non-alcoholic fatty liver disease with type 2 diabetes,empagliflozin and liraglutide can significantly reduce blood glucose and regulate liver function,and liraglutide can better correct blood lipid levels,which has obvious advantages over metformin.
维普
万方数据
